Kitov Pharma Provides Corporate Update and Reports First Half 2018 Financial Results Tel Aviv, Israel

Pharma Provides Corporate Update and Reports First Half 2018 Financial Results

Tel Aviv, Israel, August 29, 2018 - Kitov

Pharma Ltd. (NASDAQ/TASE: KTOV), an innovative biopharmaceutical company, today provided a corporate update and reported financial

results for the six months ended June 30, 2018.

"The first half of 2018 has been

a transformational period for Kitov," said Kitov's CEO, Isaac Israel. "Most importantly, we received U.S. Food

and Drug Administration (FDA) approval to market Consensi (amlodipine and celecoxib) oral tablets for the simultaneous treatment

of pain caused by osteoarthritis, as well as hypertension. We are now focused on securing an optimal U.S. commercialization partner

for Consensi in the U.S. who has the capability to execute a successful product launch and provide Kitov with a solid on-going

"Moreover, we are excited about

the continued progress we have achieved in advancing NT-219, our promising cancer therapy drug candidate," continued

Mr. Israel. "We have generated compelling pre-clinical results for NT-219 to date, and expect to submit an Investigational New

Drug application to the FDA and to initiate clinical trials for NT-219 in 2019."

"Finally, following our recent fund

raise of approximately $8.1 million in gross proceeds, we are supported by a strong balance sheet with approximately $11.8 million

in cash and deposits and no debt as of June 30, 2018," concluded Mr. Israel.

Recent Corporate Highlights:

Expected Upcoming Milestones:

information contained below should be read in conjunction with (1) our Unaudited Condensed Consolidated Interim Financial Statements

as of June 30, 2018, and for the six months then ended; and, (2) our audited consolidated financial statements for the year ended

December 31, 2017, which appears in the Company's Annual Report on Form 20-F filed with the Securities and Exchange Commission

on March 5, 2018, as well as the other information contained in such Annual Report on Form 20-F and in our Registration Statements

and Prospectuses filed with the SEC.

Results for Six Months Ended June 30, 2018

for the six months ended June 30, 2018 were $1.0 million, consisting of an up-front payment from Changshan Biochemical Pharmaceutical

Co., Ltd. in accordance with the terms of the License Agreement for Consensi . There were no revenues in the six months

ended June 30, 2017.

and development expenses for the six months ended June 30, 2018, were $2.8 million, an increase of 13%, compared to $2.5 million

for the six months ended June 30, 2017. The increase resulted primarily from higher expenses related to pre-clinical trials for

NT-219, partially offset by a reduction in expenses related to Consensi , following submission of the NDA in 2017 and receipt

of FDA approval in May 2018.

and administrative expenses for the six months ended June 30, 2018, were $3.4 million, an increase of 34%, compared to $2.5 million

for the six months ended June 30, 2017. The increase resulted from increases in legal fees, as well as increases in business development

and other advisory services and officers' and directors' insurance.

income for the six months ended June 30, 2018, was $0.9 million, representing a reversal of other expenses of $1.0 million for

the six months ended June 30, 2017, which consisted of the fair value of rights granted to Taoz, a minority shareholder in TyrNovo,

upon the Company's acquisition of Taoz's shares in TyrNovo in June 2018, net of expenses associated with the acquisition.

expense for the six months ended June 30, 2018, was $0.8 million and was primarily related to the valuation of non-registered

warrants issued in 2017 and expenses related to non-registered warrants issued in 2018. Finance income for the six months ended

June 30, 2017, was $0.1 million and was primarily related to interest on bank deposits.

Company's net loss for the six months ended June 30, 2018, amounted to $5.2 million, compared with a loss of $6.0 million

for the corresponding period in 2017.

Kitov Pharmaceuticals

Pharma (Kitov Pharma Ltd.; NASDAQ/TASE: KTOV) is an innovative biopharmaceutical drug development company. Leveraging deep

regulatory and clinical-trial expertise, Kitov's veteran team of healthcare and business professionals maintains a proven

track record in streamlined end-to-end drug development and approval. Kitov's flagship combination drug, Consensi

achieved the primary efficacy endpoints for its Phase III and Phase III/IV clinical trials, and was approved by the FDA for patients

suffering from osteoarthritis pain and hypertension. NT219, which is developed by its majority-owned subsidiary, TyrNovo Ltd.,

is a novel patented small molecule designed to overcome cancer drug resistance that is currently in pre-clinical development.

By lowering development risk and cost through fast-track regulatory approval of innovative therapeutic candidates, Kitov is committed

to delivering rapid ROI and long-term potential to investors, while making a meaningful impact on people's lives.

in this press release that are forward-looking and not statements of historical fact are forward-looking statements within the

meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may

be identified by the use of forward-looking words such as "believe", "expect", "intend", "plan",

"may", "should", "could", "might", "seek", "target", "will",

"project", "forecast", "continue" or "anticipate" or their negatives or variations

of these words or other comparable words or by the fact that these statements do not relate strictly to historical matters. You

should not place undue reliance on these forward-looking statements, which are not guarantees of future performance. Forward-looking

statements reflect our current views, expectations, beliefs or intentions with respect to future events, and are subject to a

number of assumptions, involve known and unknown risks, many of which are beyond our control, as well as uncertainties and other

factors that may cause our actual results, performance or achievements to be significantly different from any future results,

performance or achievements expressed or implied by the forward-looking statements. Important factors that could cause or contribute

to such differences include, among others, risks relating to: risks and uncertainties associated with obtaining court approval

of the proposed settlement of the two U.S. shareholder class-action lawsuits, the number of plaintiffs who may opt-out of the

proposed settlement, and whether any proposed settlement is appealed; the fact that drug development and commercialization involves

a lengthy and expensive process with uncertain outcomes; our ability to successfully develop and commercialize our pharmaceutical

products; the expense, length, progress and results of any clinical trials; the lack of sufficient funding to finance the clinical

trials; the impact of any changes in regulation and legislation that could affect the pharmaceutical industry; the difficulty

in receiving the regulatory approvals necessary in order to commercialize our products; the difficulty of predicting actions of

the U.S. Food and Drug Administration or any other applicable regulator of pharmaceutical products; the regulatory environment

and changes in the health policies and regimes in the countries in which we operate; the uncertainty surrounding the actual market

reception to our pharmaceutical products once cleared for marketing in a particular market; the introduction of competing products;

patents attained by competitors; dependence on the effectiveness of our patents and other protections for innovative products;

our ability to obtain, maintain and defend issued patents with protective claims; the commencement of any patent interference

or infringement action; our ability to prevail, obtain a favorable decision or recover damages in any such action; and the exposure

to litigation, including patent litigation, and/or regulatory actions; the continued uncertainty surrounding an investigation

by the Israel Securities Authority into our historical public disclosures and the potential impact of such investigation on the

trading of our securities or on our clinical, commercial and other business relationships; or on receiving the regulatory approvals

necessary in order to commercialize our products; the uncertainty of the impact of such investigation and/or the proposed settlement

of the two U.S. shareholder class-action lawsuits on the Israeli class action civil litigation in connection with the investigation

which is still continuing, and other factors that are discussed in our in our Annual Report on Form 20-F for the year ended December

31, 2017 and in our other filings with the SEC, including our cautionary discussion of risks and uncertainties under Risk

Factors' in our Registration Statements, Prospectuses and Annual Reports. These are factors that we believe could cause

our actual results to differ materially from expected results. Other factors besides those we have listed could also adversely

affect us. Any forward-looking statement in this press release speaks only as of the date which it is made. We disclaim any intention

or obligation to publicly update or revise any forward-looking statement, or other information contained herein, whether as a

result of new information, future events or otherwise, except as required by applicable law. You are advised, however, to consult

any additional disclosures we make in our reports to the SEC, which are available on the SEC's website, http://www.sec.gov

Consolidated Unaudited Interim Statements of Financial Position as of

Consolidated Unaudited Interim Statements of Operations and Other Comprehensive Income

Simcha Rock, Chief Financial Officer and Director

+972-3- 9333121 ext. #105